Current expertise and future directions in drug discovery: an Oxford-Industry conversation
This event is now fully subscribed. Please contact michael.ohagan@chembiohub.ox.ac.uk to join the waitlist.
For list of speakers and registration, visit chembiohub.ox.ac.uk/conversation

This event showcases top chemical biology research from labs at Oxford. Particular emphasis is placed on linking basic chemical biology research to work in the clinic.

The first session of the day looks at disease-agnostic technologies to aid drug discovery. The second session features work on targets and pathways applied to a variety of illnesses. The third session focuses on therapeutic interventions for neurodegenerative diseases.

Each session features top-class science presentations from a broad range of Oxford’s biomedical and physical science departments, with speakers from industry giving their perspective throughout the day. This sets the stage for a round-table discussion between opinion leaders from across Oxford and industry. The conversation will focus on how we can best work together to translate ideas into new medicines.

The symposium will bring together 200 delegates including Oxford researchers, industry colleagues and technology transfer professionals. In doing so, it will provide the ideal forum for discussion and lead to lasting collaborative relationships.

Networking breaks and poster sessions will allow discussion to continue outside of the lecture theatre. The day will finish with a wine reception in the common room of the Andrew Wiles building, which provides a beautiful view of the 18th century Radcliffe Observatory.
Date: 31 July 2015, 9:00 (Friday, 14th week, Trinity 2015)
Venue: Mathematical Institute, Woodstock Road OX2 6GG
Speakers: Speaker to be announced
Organising department: Chemical Biology
Organiser contact email address: michael.ohagan@chembiohub.ox.ac.uk
Part of: ChemBio Hub Events
Booking required?: Required
Booking url: https://chembiohub.ox.ac.uk/conversation
Audience: Members of the University only
Editors: Anne Bowtell, Michael O'Hagan